Rothschild & Co Redburn downgraded FactSet Research Systems Inc. (FDS) from Neutral to Sell, cutting its price target to $215, citing eroding pricing power and increased AI disintermediation risks in its challenged markets. This downgrade comes despite RBC Capital previously reiterating a Sector Perform rating, with expectations of an Annual Subscription Value (ASV) beat for FactSet's third quarter. FactSet is a global financial digital platform and analytics provider, but analysts are concerned about its valuation in light of these growing pressures.

This article details the OxiClean Versatile Stain Remover from Church & Dwight Co., highlighting its oxygen-based chemistry for tackling stains on various surfaces like clothes and carpets. It describes the product's effectiveness, usage, and integration within the broader OxiClean family, emphasizing its appeal to households seeking a non-chlorine bleach solution. The piece also touches on Church & Dwight's market position, with OxiClean being a key brand alongside Arm & Hammer, and notes the product's availability and target consumer.

This page on TradingView provides actuals and estimates for Dow, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh (BMFBOVESPA:D1OW34). It allows users to explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.

This article displays the enterprise value to EBITDA forward for Equinix, Inc. (NASDAQ: EQIX). It includes basic company information and highlights that the market is currently closed with no trades. The data provided is from FactSet Research Systems Inc. and ICE Data Services.

Rothschild & Co Redburn has downgraded FactSet Research Systems Inc. (FDS) to Sell, citing concerns over eroding market dominance, weakening pricing power, and increasing AI disintermediation risks. This follows a previous downgrade by RBC Capital, which lowered its price target while maintaining a Sector Perform rating. The analysts suggest that while FactSet is a global financial data and analytics provider, other AI stocks may offer better upside potential with less downside risk.

This article provides details on Molson Coors Beverage Company Class B (MIL:1TAP) stock, including its current price, market capitalization, volatility, and historical performance. It also covers financial actuals and estimates, analysts' price targets, and upcoming earnings dates, along with dividend information.

Texas Capital has initiated coverage on The Andersons, Inc. (NASDAQ: ANDE) with a Buy rating and a $110 price target, citing the company's "differentiated exposure" to the U.S. ethanol and renewable feedstocks industries. The firm noted Andersons' vertically integrated business model positions it well to benefit from a constructive macro environment for ethanol. The company's CEO highlighted significant progress in renewable energy projects and strong financial performance in Q1 2026, including qualifying for 45Z tax credits.

Amrize Ltd (AMRZ) has a current stock price of $55.88, with analysts providing a 1-year price target of $63.73, and a maximum estimate of $70.00 and minimum of $53.15. The stock has shown positive performance recently, with increases over the past week, month, and year. The company's next earnings report is expected on August 3, 2026, and its technical analysis currently indicates a "strong buy" rating.

This article reviews Alcon's market performance on a Friday, noting its Swiss listing on SIX alongside healthcare peers like Novartis and Roche. The author highlights that Alcon's position as a Swiss defensive stock often draws attention during cautious global equity sentiment, especially given weaker Asian equities and renewed pressure on technology sentiment. Alcon manufactures eye care products, including contact lenses and surgical equipment, and its shares are traded in Swiss francs on the SIX exchange.

This article provides the "Price to earnings forward" value for AN2 Therapeutics, Inc. (NASDAQ: ANTX) within the context of TradingView's financial data. It indicates the stock's market status and references the data sources used. The specific financial value is not detailed, but the article focuses on its presentation on the platform.